ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2014
Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis.European journal of clinical pharmacology · 2021Pooled it
- Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.Diseases (Basel, Switzerland) · 2025Review
- Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD).Journal of clinical & translational endocrinology · 2024Review
- The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics.Psychiatry investigation · 2023Article
- Article
- A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity.Adolescent health, medicine and therapeutics · 2023Review
- Energy imbalance: obesity, associated comorbidities, prevention, management and public health implications.Advances in obesity, weight management & control · 2020Article
- Article
- Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects.Annals of translational medicine · 2019Review
- Obesity: Current and potential pharmacotherapeutics and targets.Pharmacology & therapeutics · 2017Review
- Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.Current hypertension reports · 2016Review
- Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2016Article
- Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives.Patient preference and adherence · 2016Review
- Next generation of weight management medications: implications for diabetes and CVD risk.Current cardiology reports · 2015Review
- 2014 EASO Position Statement on the Use of Anti-Obesity Drugs.Obesity facts · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release topiramate (phentermine/topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. Combination phentermine/topiramate ER is associated with greater weight loss compared to its constituent monotherapy, with a more favorable adverse effect profile. Phentermine/topiramate ER also appears to have beneficial effects on cardiometabolic risk, although longer-term cardiovascular safety data are required. While there are no head-to-head studies among the currently available obesity pharmacotherapy agents, phentermine/topiramate ER appears to have a superior weight loss profile. This review will discuss the epidemiology, natural history, and cardiometabolic risk associated with obesity, provide an overview on current obesity pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the FDA's approval of both phentermine/topiramate ER and lorcaserin as pharmacotherapy for a long-term obesity intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.